Literature DB >> 1372891

The cystic fibrosis transmembrane conductance regulator. Effects of the most common cystic fibrosis-causing mutation on the secondary structure and stability of a synthetic peptide.

P J Thomas1, P Shenbagamurthi, J Sondek, J M Hullihen, P L Pedersen.   

Abstract

Deletion of phenylalanine 508 (delta Phe-508) in the cystic fibrosis transmembrane conductance regulator (CFTR) protein causes approximately 70% of all cases of cystic fibrosis. This residue lies in a region of the protein that we have synthesized chemically and shown to bind adenine nucleotides (Thomas, P. J., Shenbagamurthi, P., Ysern, X., and Pedersen, P. L. (1991) Science 251, 555-557). A peptide lacking this critical residue, but otherwise corresponding to this crucial part of the protein, now also has been chemically synthesized and purified. This mutant peptide (P-66) exhibits a significant loss of beta-sheet structure as compared with the wild type peptide (P-67). Furthermore, urea denaturation of peptide structure reveals that P-66 is less stable than P-67. Although under non-denaturing conditions both peptides bind adenine nucleotides with high affinity, the loss of structural stability is reflected in the binding function of the peptides. Thus, P-67, in contrast to P-66, retains a significant capacity for nucleotide binding in 4 M urea. These results suggest a model for impaired delta Phe-508 CFTR function.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1372891

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

Review 1.  Cystic fibrosis as a disease of misprocessing of the cystic fibrosis transmembrane conductance regulator glycoprotein.

Authors:  J R Riordan
Journal:  Am J Hum Genet       Date:  1999-06       Impact factor: 11.025

2.  Structural cues involved in endoplasmic reticulum degradation of G85E and G91R mutant cystic fibrosis transmembrane conductance regulator.

Authors:  X Xiong; A Bragin; J H Widdicombe; J Cohn; W R Skach
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 3.  CFTR chloride channel in the apical compartments: spatiotemporal coupling to its interacting partners.

Authors:  Chunying Li; Anjaparavanda P Naren
Journal:  Integr Biol (Camb)       Date:  2010-03-05       Impact factor: 2.192

Review 4.  Cystic fibrosis: a brief look at some highlights of a decade of research focused on elucidating and correcting the molecular basis of the disease.

Authors:  Y H Ko; P L Pedersen
Journal:  J Bioenerg Biomembr       Date:  2001-12       Impact factor: 2.945

5.  Co-translational effects of temperature on membrane insertion and orientation of P-glycoprotein sequences.

Authors:  J T Zhang; C H Chong
Journal:  Mol Cell Biochem       Date:  1996-06-07       Impact factor: 3.396

Review 6.  Frontiers in research on cystic fibrosis: understanding its molecular and chemical basis and relationship to the pathogenesis of the disease.

Authors:  Y H Ko; P L Pedersen
Journal:  J Bioenerg Biomembr       Date:  1997-10       Impact factor: 2.945

7.  Requirements for efficient correction of ΔF508 CFTR revealed by analyses of evolved sequences.

Authors:  Juan L Mendoza; André Schmidt; Qin Li; Emmanuel Nuvaga; Tyler Barrett; Robert J Bridges; Andrew P Feranchak; Chad A Brautigam; Philip J Thomas
Journal:  Cell       Date:  2012-01-20       Impact factor: 41.582

8.  Effects of the delta F508 mutation on the structure, function, and folding of the first nucleotide-binding domain of CFTR.

Authors:  P J Thomas; P L Pedersen
Journal:  J Bioenerg Biomembr       Date:  1993-02       Impact factor: 2.945

9.  Characterization of an allele-nonspecific intragenic suppressor in the yeast plasma membrane H+-ATPase gene (Pma1).

Authors:  A M Maldonado; N de la Fuente; F Portillo
Journal:  Genetics       Date:  1998-09       Impact factor: 4.562

Review 10.  Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies.

Authors:  James L Kreindler
Journal:  Pharmacol Ther       Date:  2009-11-10       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.